We are live on ! Find out more
RI

RTW Investments Portfolio holdings

AUM $10B
1-Year Est. Return 135.35%
This Fund
S&P 500
This Quarter Est. Return
+14.09%
1 Year Est. Return
+135.35%
3 Year Est. Return
+383.62%
5 Year Est. Return
+523.94%
10 Year Est. Return
+15,981.64%
AUM
$1.87B
AUM Growth
+$407M
Cap. Flow
+$334M
Cap. Flow %
17.86%
Top 10 Hldgs %
60.38%
Holding
58
New
8
Increased
29
Reduced
10
Closed
6

Top Buys

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$105M
2
STOK icon
Stoke Therapeutics
STOK
+$90.1M
3
MIST icon
Milestone Pharmaceuticals
MIST
+$72.6M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$32.3M
5
ILMN icon
Illumina
ILMN
+$26.6M

Top Sells

Rank Stock Value
1
LIVN icon
LivaNova
LIVN
+$42.3M
2
SIBN icon
SI-BONE Inc
SIBN
+$23.9M
3
CNCE
Concert Pharmaceuticals, Inc.
CNCE
+$20.4M
4
WVE icon
Wave Life Sciences
WVE
+$17M
5
ARWR icon
Arrowhead Research
ARWR
+$8.95M

Sector Composition

Rank Sector Weight
1 Healthcare 94.26%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RGNX icon
26
Regenxbio
RGNX
$620M
$18.9M 1.01%
368,040
-83,142
-18% -$4.15M
LJPC
27
DELISTED
La Jolla Pharmaceutical Company
LJPC
$18.6M 0.99%
2,011,340
+1,710,174
+568% +$12.9M
ARVN icon
28
Arvinas
ARVN
$518M
$17.8M 0.95%
807,870
-108,644
-12% -$2.28M
TMDX icon
29
Transmedics
TMDX
$2.64B
$14.7M 0.79%
+507,007
New +$13.8M
KIDS icon
30
OrthoPediatrics
KIDS
$519M
$14.7M 0.78%
376,647
-51,495
-12% -$2.08M
QTNT
31
DELISTED
Quotient Limited Ordinary Shares
QTNT
$14.4M 0.77%
+38,601
New +$13.8M
JNJ icon
32
Johnson & Johnson
JNJ
$618B
$13.1M 0.7%
93,912
+9,298
+11% +$1.29M
ODT
33
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$12.4M 0.66%
339,156
+7,916
+2% +$190K
ABUS icon
34
Arbutus Biopharma
ABUS
$857M
$11.5M 0.61%
5,533,093
+22,870
+0.4% +$58.5K
QURE icon
35
uniQure
QURE
$3.03B
$11.3M 0.6%
144,595
-9,463
-6% -$603K
CTMX icon
36
CytomX Therapeutics
CTMX
$675M
$11.1M 0.59%
988,319
+23,067
+2% +$242K
SILK
37
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$10.8M 0.58%
+223,722
New +$9.52M
MYGN icon
38
Myriad Genetics
MYGN
$270M
$10.5M 0.56%
376,586
+109,095
+41% +$3.08M
PRNB
39
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$8.99M 0.48%
270,948
-185,000
-41% -$5.78M
BWAY
40
Brainsway
BWAY
$611M
$6.26M 0.33%
+1,194,432
New +$6.22M
CHAC.U
41
DELISTED
Chardan Healthcare Acquisition Corp.
CHAC.U
$6.11M 0.33%
600,000
– –
PSNL icon
42
Personalis
PSNL
$1.35B
$6.11M 0.33%
+225,000
New +$6.36M
CDNA icon
43
CareDx
CDNA
$2.26B
$5.57M 0.3%
154,616
-67,047
-30% -$2.15M
ARGX icon
44
argenx
ARGX
$53.4B
$4.45M 0.24%
31,448
+734
+2% +$93.2K
MOTS
45
DELISTED
Motus GI Holdings, Inc. Common Stock
MOTS
$3.41M 0.18%
3,754
+2,222
+145% +$2.48M
STIM icon
46
Neuronetics
STIM
$138M
$2.1M 0.11%
168,274
+1,713
+1% +$24.2K
VIVE
47
DELISTED
VIVEVE MED INC
VIVE
$1.7M 0.09%
4,481
– –
VRAY
48
DELISTED
ViewRay, Inc.
VRAY
$1.4M 0.07%
159,247
– –
SLDB icon
49
Solid Biosciences
SLDB
$794M
$835K 0.04%
9,682
+226
+2% +$24.6K
OPTN
50
DELISTED
OptiNose
OPTN
$620K 0.03%
5,841
+331
+6% +$43.6K
1
2
3

Similar funds

HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
FPAS
Focus Partners Advisor Solutions Saint Louis, Missouri $9.92B AUM 21.52% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return

RTW Investments's Q2 2019 Portfolio in Review

As of Q2 2019, RTW Investments held 58 positions worth $1.87B, up 28% from $1.47B the previous quarter. Its ten largest holdings account for 60% of the portfolio.

RTW Investments deployed $334M of net new capital in Q2 2019, opening 8 new positions and adding to 29 existing holdings. Its largest new stake was Stoke Therapeutics: 3,355,466 shares worth $92.6M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 92% a quarter earlier.

On the sell side, the largest reduction was Arrowhead Research, an estimated $8.95M trimmed.

  • RTW Investments's largest Q2 2019 buy was Stoke Therapeutics: 3,355,466 shares worth $92.6M.
  • RTW Investments added most to Alnylam Pharmaceuticals in Q2 2019, an estimated $105M increase.
  • RTW Investments's biggest Q2 2019 reduction was Arrowhead Research, cutting an estimated $8.95M.
  • RTW Investments fully exited LivaNova in Q2 2019, selling an estimated $42.3M.
  • RTW Investments's ten largest holdings make up 60% of its $1.87B portfolio in Q2 2019.
  • RTW Investments opened 8 new positions and closed 6 in Q2 2019.
  • RTW Investments's portfolio value rose 28% quarter-over-quarter to $1.87B.

Based on RTW Investments's 13F filing for Q2 2019, filed 14 Aug 2019.